Henry Schein (HSIC) Stock Rating Reaffirmed by JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated their neutral rating on shares of Henry Schein (NASDAQ:HSIC) in a research report sent to investors on Thursday morning, Marketbeat reports. They currently have a $77.00 target price on the stock, down from their previous target price of $79.00.

A number of other brokerages have also weighed in on HSIC. Jefferies Group reaffirmed a hold rating and set a $89.00 target price on shares of Henry Schein in a research note on Friday, October 20th. Robert W. Baird set a $95.00 target price on shares of Henry Schein and gave the company a buy rating in a research note on Thursday, October 19th. Stifel Nicolaus reaffirmed a hold rating and set a $89.00 target price on shares of Henry Schein in a research note on Thursday, October 19th. Leerink Swann reaffirmed a hold rating on shares of Henry Schein in a research note on Tuesday, February 13th. Finally, Evercore ISI began coverage on shares of Henry Schein in a research note on Thursday, January 4th. They set an outperform rating and a $81.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $83.71.

Shares of Henry Schein (NASDAQ:HSIC) opened at $69.52 on Thursday. The firm has a market cap of $10,911.47, a PE ratio of 19.50, a PEG ratio of 1.78 and a beta of 1.00. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.86 and a current ratio of 1.55. Henry Schein has a 52 week low of $63.01 and a 52 week high of $93.50.

In related news, Director Barry J. Alperin sold 5,796 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $70.76, for a total transaction of $410,124.96. Following the sale, the director now owns 48,172 shares of the company’s stock, valued at $3,408,650.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.19% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. We Are One Seven LLC bought a new stake in Henry Schein during the fourth quarter worth about $289,000. OLD Mutual Customised Solutions Proprietary Ltd. lifted its stake in shares of Henry Schein by 38.8% in the fourth quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 11,100 shares of the company’s stock worth $776,000 after buying an additional 3,100 shares in the last quarter. Stone Run Capital LLC bought a new position in shares of Henry Schein in the fourth quarter worth approximately $3,334,000. MetLife Investment Advisors LLC bought a new position in shares of Henry Schein in the fourth quarter worth approximately $3,394,000. Finally, MainStreet Investment Advisors LLC bought a new position in shares of Henry Schein in the fourth quarter worth approximately $577,000. 88.58% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Henry Schein (HSIC) Stock Rating Reaffirmed by JPMorgan Chase & Co.” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://weekherald.com/2018/02/19/henry-schein-hsic-stock-rating-reaffirmed-by-jpmorgan-chase-co-2.html.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply